Fetzima (Fetzima) Rx Price Comparison: US vs Canada

Our most recent US pharmacy data shows a low of roughly $532.92 for Fetzima with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

We found Canadian pricing for Fetzima starting near $4.30 per tablet in USD terms. That's before any shipping charge, which the table above breaks out separately.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. Check the comparison table above for the specific numbers on Fetzima.

Generic and brand-name pricing for Fetzima is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

Your cost for Fetzima with insurance depends entirely on your specific plan's formulary, tier placement, and copay structure. Your pharmacist or insurance provider can give you the exact out-of-pocket amount. In some cases, the price available through a pharmacy discount program might be lower than your insurance copay. It can be helpful to compare the pricing options available at your pharmacy before filling your prescription.

Fetzima is generally covered under Medicare prescription drug plans, including Part D and Medicare Advantage plans with pharmacy benefits. However, coverage details and patient cost-sharing (like copays or coinsurance) vary by plan and can still result in a high out-of-pocket expense. Prices available through independent prescription savings programs can sometimes offer an alternative that may be less expensive than your Medicare copay. Because drug prices and plan formularies can change, comparing costs at the pharmacy for each refill is a prudent practice.

No. Fetzima is the brand name for the active ingredient levomilnacipran, and there is currently no FDA-approved generic equivalent on the market.